دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis
Brent Cao a,*, Melissa Kim a , Natalie M. Reizine b , Daniel M. Moreira
doi : 10.1016/j.euo.2023.01.001
Volume 6, Issue 3, June 2023, Pages 237-250
Androgen receptor signaling inhibitor (ARSi) agents are emerging as standard treatments for prostate cancer across the disease spectrum, but much remains unknown regarding how their side-effect profiles compare.
A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer
Elisabeth Grobet-Jeandin a,b , Louis Lenfant a , Carmen Mir c , Gianluca Giannarini d , Antonio Alcaraz e , Maarten Albersen f,g , Alberto Breda h , Alberto Briganti i , Morgan Roupreˆt a , Thomas Seisen a,*, on behalf of the EAU Section of Oncological Urology (ESOU) Board
doi : 10.1016/j.euo.2023.02.008
Volume 6, Issue 3, June 2023, Pages 251-262
Bladder-sparing strategies (BSSs) have been proposed for the treatment of muscle-invasive bladder cancer (MIBC) patients achieving clinical complete response (cCR) to initial systemic treatment to avoid toxicity related to radical cystectomy.
Adaptive Immunity in Genitourinary Cancers
Madhuri Koti a,*, Trinity Bivalacqua b , Peter C. Black c , Toni Cathomen d , Matthew D. Galsky e , James L. Gulley f , Molly A. Ingersoll g,h , Ashish M. Kamat i , Wassim Kassouf j , D. Robert Siemens k , Jianjun Gao
doi : 10.1016/j.euo.2023.03.002
Volume 6, Issue 3, June 2023, Pages 263-272
While urothelial and renal cell cancers have exhibited modest responses to novel immune checkpoint inhibitors targeting the programmed death ligand 1 and its receptor, response rates in patients with prostate cancer have remained poor. The factors underlying suboptimal outcomes observed in patients treated with novel immunotherapies are still to be resolved.
Leveraging the Tumor Immune Microenvironment To Overcome Genitourinary Cancers
Matteo Bellone a , Anna Mondino
doi : 10.1016/j.euo.2023.04.002
Volume 6, Issue 3, June 2023, Pages 273-274
Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion
Daniel Gorovets a,*, Andreas G. Wibmer b , Assaf Moore a,c , Stephanie Lobaugh d , Zhigang Zhang d , Marisa Kollmeier a , Sean McBride a , Michael J. Zelefsky
doi : 10.1016/j.euo.2022.02.005
Volume 6, Issue 3, June 2023, Pages 275-281
A positive post-treatment prostate biopsy following definitive radiotherapy carries significant prognostic implications.
Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer
Justin R. Gregg a,*, Jeri Kim w , Christopher Logothetis b , Sam Hanash c , Xiaotao Zhang d , Ganiraju Manyam e , Kenneth Muir f,g , UKGPCS Collaborative Group h , Graham G. Giles i,j,k , Janet L. Stanford l,m , Sonja I. Berndt n , Manolis Kogevinas o,p,q,r , Hermann Brenner s,t,u , Rosalind A. Eeles h,v , PRACTICAL Consortium h , Peng Wei e,y, Carrie R. Daniel
doi : 10.1016/j.euo.2022.07.008
Volume 6, Issue 3, June 2023, Pages 282-288
Coffee intake may lower prostate cancer risk and progression, but postdiagnosis outcomes by caffeine metabolism genotype are not well characterized.
Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer
Wei Phin Tan a,b,c,y, Srinath Kotamarti a,y, Alexandria Ayala b , Rachael Mahle b , Emily Chen b , Rohith Arcot a , Andrew Chang a,d , Zoe Michael a , Denis Seguier a , Thomas J. Polascik
doi : 10.1016/j.euo.2023.02.007
Volume 6, Issue 3, June 2023, Pages 289-294
There is no consensus on the optimal approach for salvage local therapy in radiation-resistant/recurrent prostate cancer (RRPC).
An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study
David Eldred-Evans a,b , Henry Tam c , Heminder Sokhi d,e , Anwar R. Padhani e , Martin Connor a,b , Derek Price f , Martin Gammon g , Natalia Klimowska-Nassar h,i , Paula Burak h,i , Emily Day h,i , Mathias Winkler a,b , Francesca Fiorentino h,i , Hashim U. Ahmed
doi : 10.1016/j.euo.2023.03.009
Volume 6, Issue 3, June 2023, Pages 295-302
The use of prostate-specific antigen (PSA) testing to screen for prostate cancer has been fraught with under- and overdiagnosis. Short, noncontrast magnetic resonance imaging (MRI) might detect more grade group ≥2 cancers with similar rates of biopsy.
Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study
Paul Archer a , Giulia Marvaso b,c , Beatrice Detti d , Francesca Colombo b,c , Giulio Francolini d , Benjamin Vandendorpe a , Marie Albert Thananayagam e , Manon Baty f , Renaud De Crevoisier f , Filippo Alongi g,h , Luca Nicosia g , Nathaniel Scher i,j , Alain Toledano i,j , Nadia Di Muzio k,l , Andrei Fodor k , Thomas Zilli m,n , Ciro Franzese o,p , Marta Scorsetti o,p , Mohamed Shelan q , Luca Triggiani r , Estelle Aymes e , Marie-Ce´cile Le Deley e , Barbara Alicja Jereczek-Fossa b,c , David Pasquier
doi : 10.1016/j.euo.2023.03.005
Volume 6, Issue 3, June 2023, Pages 303-310
Management of local recurrence of prostate cancer (PCa) in the prostatic bed after radical prostatectomy (RP) and radiotherapy remains challenging.
Salvage Reirradiation Options for Treating Local Recurrence After Previous Prostatectomy and Radiotherapy: Where Do We Stand?
Jim Zhong a,b,c,d , Peter Hoskin
doi : 10.1016/j.euo.2023.04.003
Volume 6, Issue 3, June 2023, Pages 311-312
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer
Brant A. Inman a,*, Noah M. Hahn b,c , Kelly Stratton d , Ryan Kopp e,f , Alex Sankin g , Eila Skinner h , Kamal Pohar i , Benjamin A. Gartrell j , Song Pham k , Deepali Rishipathak k , Sanjeev Mariathasan k , Nicole Davarpanah k , Corey Carter k , Gary D. Steinberg
doi : 10.1016/j.euo.2023.01.013
Volume 6, Issue 3, June 2023, Pages 313-320
Bacille Calmette-Guérin (BCG) is the standard therapy after transurethral resection of bladder tumour for high-risk non–muscle-invasive bladder cancer (NMIBC). However, post-BCG recurrence/progression occurs frequently, and noncystectomy options are limited.
The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities
Fady Ghali a , Jonathan L. Wright a,b , Petros Grivas
doi : 10.1016/j.euo.2023.03.006
Volume 6, Issue 3, June 2023, Pages 321-322
Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma
Zine-Eddine Khene a,b , Pierre Bigot c , Nicolas Doumerc d , Idir Ouzaid e , Romain Boissier f , Franc¸ ois-Xavier Nouhaud g , Laurence Albiges h , Jean-Christophe Bernhard i , Alexandre Ingels j , Delphine Borchiellini k , Sole`ne Kammerer-Jacquet l , Nathalie Rioux-Leclercq l , Morgan Roupret m , Oscar Acosta b , Renaud De Crevoisier b,n , Karim Bensalah a
doi : 10.1016/j.euo.2022.07.007
Volume 6, Issue 3, June 2023, Pages 323-330
Predictive tools can be useful for adapting surveillance or including patients in adjuvant trials after surgical resection of nonmetastatic renal cell carcinoma (RCC). Current models have been built using traditional statistical modelling and prespecified variables, which limits their performance.
Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma
Neil T. Mason a , Vidhu B. Joshi b , Jacob J. Adashek c , Youngchul Kim d , Savan S. Shah e , Amy M. Schneider f , Juskaran Chadha g , Heather S.L. Jim h , Margaret M. Byrne h , Scott M. Gilbert g , Brandon J. Manley g , Philippe E. Spiess g , Jad Chahoud
doi : 10.1016/j.euo.2023.01.011
Volume 6, Issue 3, June 2023, Pages 331-338
The treatment landscape for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years. Without direct comparator trials, factors such as cost effectiveness (CE) are important to guide decision-making.
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor a,y, Daniel M. Geynisman b,y, Mauricio Burotto c , Cristina Sua´rez d , Maria T. Bourlon e , Pedro C. Barata f , Shuchi Gulati g,à , Stephen Huo h , Flavia Ejzykowicz h , Steven I. Blum h , Viviana Del Tejo i , Melissa Hamilton h , Jessica R. May j , Ella X. Du k , Aozhou Wu k , Pavol Kral l , Cristina Ivanescu m , Andi Chin k , Keith A. Betts k , Chung-Han Lee n , Toni K. Choueiri a,o,p , David Cella q,*, Camillo Porta
doi : 10.1016/j.euo.2023.01.012
Volume 6, Issue 3, June 2023, Pages 339-348
The comparative efficacy and health-related quality of life (HRQoL) outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib as first-line treatments for advanced renal cell carcinoma (aRCC) have not been assessed in head-to-head trials.
Health-related Quality of Life and Cost Effectiveness of Treatment: Components to Be Included in Clinical Decision-making
Cristiane Decat Bergerot a,*, Julia Bonastre
doi : 10.1016/j.euo.2023.03.011
Volume 6, Issue 3, June 2023, Pages 349-350
Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank
Hannah Harrison a,*, Angela Wood a , Lisa Pennells a , Sabrina H. Rossi b , Matthew Callister c , Jon Cartledge d , Grant D. Stewart b , Juliet A. Usher-Smith
doi : 10.1016/j.euo.2023.02.012
Volume 6, Issue 3, June 2023, Pages 351-353
In the absence of population-based screening, addition of screening for kidney cancer to lung cancer screening could provide an efficient and low-resource means to improve early detection. In this study, we used the UK Biobank cohort (n = 442 865) to determine the performance of the Yorkshire Lung Cancer Screening Trial (YLST) eligibility criteria for selecting individuals for kidney cancer screening.
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505–16
Francesco Montorsi Marco Moschini * Alberto Briganti
doi : 10.1016/j.euo.2023.03.007
Volume 6, Issue 3, June 2023, Page 354
